Rimonabant

Rimonabant

Name Rimonabant 
CAS 168273-06-1
Melting point  230 to 240
Molecular Formula C22Cl3HN4O
Dry weight loss  less than 0.5%
PH  (10% aqueous solution) 4-7
Heavy metal  less than 10ppm
TLC  only one spot
Content  99.5%
Character  white or white crystalline powder, soluble in methanol.
Packing specification  1kg/ aluminum foil bag; 25kg/ cardboard drum
Storage  avoid light, sealed, placed in a cool place to store.

 

COA:
 

Test Items Specification Test Results
Description White crystalline powder White crystalline powder
Identification IR , UV conform Conform
Loss on drying ≤0.5ml 0.21ml
Residue on ignition Not more than 0.2% 0.06ml
Iron Not more than 0.005% 0.0018%
Heavy metals Not more than 0.001% 0.0006%
Related substances Total: Not more than 1.0%
Individual: Not more than 0.5%
0.32%
0.14%
E-isomer Not more than 0.3% 0.19%
Organic volatile impurities Conforms Conforms
Assay 99.0~101.0% 99.51%
Conclusion Conform with USP30

 
Dosage:

It is expected that the usual dose of  rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Although rimonabant can be used in patients with mild hepatic impairment, caution is advised in patients with moderate impairment. This medication is not recommended for those with severe hepatic impairment.

Rimonabant may be used cautiously in patients with mild-to-moderate renal impairment, but it is not recommended for patients who are severely renally impaired.

There are no data supporting the use of rimonabant in pediatric populations.

Rimonabant should not be given to patients with a known hypersensitivity to the agent or any compound found in the tablet formulation.

The drug is contraindicated in lactat-ing women and is not recommended for use in women who are pregnant.